News
Yelena Y. Janjigian, MD, discusses the standard approval of pembrolizumab plus trastuzumab and chemotherapy for the treatment ...
The Business Research Company's Gastroesophageal Junction Adenocarcinoma Therapeutics Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 Updated 2025 Market Reports Released ...
The trial will include patients with locally advanced or metastatic HER2-positive, PD-L1-positive gastric or gastroesophageal junction cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback